[go: up one dir, main page]

WO2020144591A3 - Preparation of purified withanoside x from withania somnifera plant materials and its medicinal use - Google Patents

Preparation of purified withanoside x from withania somnifera plant materials and its medicinal use Download PDF

Info

Publication number
WO2020144591A3
WO2020144591A3 PCT/IB2020/050114 IB2020050114W WO2020144591A3 WO 2020144591 A3 WO2020144591 A3 WO 2020144591A3 IB 2020050114 W IB2020050114 W IB 2020050114W WO 2020144591 A3 WO2020144591 A3 WO 2020144591A3
Authority
WO
WIPO (PCT)
Prior art keywords
withania somnifera
extract
solid bead
layer
preparation
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Ceased
Application number
PCT/IB2020/050114
Other languages
French (fr)
Other versions
WO2020144591A2 (en
Inventor
Antony Benny
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Individual
Original Assignee
Individual
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Individual filed Critical Individual
Publication of WO2020144591A2 publication Critical patent/WO2020144591A2/en
Publication of WO2020144591A3 publication Critical patent/WO2020144591A3/en
Anticipated expiration legal-status Critical
Ceased legal-status Critical Current

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K36/00—Medicinal preparations of undetermined constitution containing material from algae, lichens, fungi or plants, or derivatives thereof, e.g. traditional herbal medicines
    • A61K36/18—Magnoliophyta (angiosperms)
    • A61K36/185—Magnoliopsida (dicotyledons)
    • A61K36/81—Solanaceae (Potato family), e.g. tobacco, nightshade, tomato, belladonna, capsicum or jimsonweed
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/48—Preparations in capsules, e.g. of gelatin, of chocolate
    • A61K9/50—Microcapsules having a gas, liquid or semi-solid filling; Solid microparticles or pellets surrounded by a distinct coating layer, e.g. coated microspheres, coated drug crystals
    • A61K9/5073—Microcapsules having a gas, liquid or semi-solid filling; Solid microparticles or pellets surrounded by a distinct coating layer, e.g. coated microspheres, coated drug crystals having two or more different coatings optionally including drug-containing subcoatings
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/48—Preparations in capsules, e.g. of gelatin, of chocolate
    • A61K9/50—Microcapsules having a gas, liquid or semi-solid filling; Solid microparticles or pellets surrounded by a distinct coating layer, e.g. coated microspheres, coated drug crystals
    • A61K9/5073—Microcapsules having a gas, liquid or semi-solid filling; Solid microparticles or pellets surrounded by a distinct coating layer, e.g. coated microspheres, coated drug crystals having two or more different coatings optionally including drug-containing subcoatings
    • A61K9/5078—Microcapsules having a gas, liquid or semi-solid filling; Solid microparticles or pellets surrounded by a distinct coating layer, e.g. coated microspheres, coated drug crystals having two or more different coatings optionally including drug-containing subcoatings with drug-free core
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K2236/00—Isolation or extraction methods of medicinal preparations of undetermined constitution containing material from algae, lichens, fungi or plants, or derivatives thereof, e.g. traditional herbal medicine

Landscapes

  • Health & Medical Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Natural Medicines & Medicinal Plants (AREA)
  • Public Health (AREA)
  • Chemical & Material Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Veterinary Medicine (AREA)
  • Epidemiology (AREA)
  • Alternative & Traditional Medicine (AREA)
  • Biotechnology (AREA)
  • Botany (AREA)
  • Medical Informatics (AREA)
  • Microbiology (AREA)
  • Mycology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicinal Preparation (AREA)

Abstract

The invention relates to a delivery system for Withania somnifera composition, the core is characterised by a solid bead and a layer of Withanias omnifera extract covering said solid bead in a dosage form. It comprises of a core characterised by a solid bead made of any one or more compound selected from the group of Sugars, oligosaccharides, polysaccharides and their derivatives, a layer of Withania somnifera extract covering said solid bead, and a layer of protective system, so that it protects the Withania somnifera extract from acidic environment of gastric juice in a stomach. The dose form comprises 5% to 20% withanolide glycoside by weight while Withania somnifera extract is standardised with 2% to 35% withanolide glycoside by weight. Method of preparing Withania somnifera extract as well as methodof preparation of dosage form of Withania somnifera composition is disclosed here. Withania somnifera Composition is effective in reducing stress, anxiety, depression, and sleep deprivation.
PCT/IB2020/050114 2019-01-09 2020-01-08 Preparation of purified withanoside x from withania somnifera plant materials and its medicinal use for the treatment of health disorders Ceased WO2020144591A2 (en)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
IN201941001044 2019-01-09
IN201941001044 2019-01-09

Publications (2)

Publication Number Publication Date
WO2020144591A2 WO2020144591A2 (en) 2020-07-16
WO2020144591A3 true WO2020144591A3 (en) 2020-09-03

Family

ID=71521437

Family Applications (1)

Application Number Title Priority Date Filing Date
PCT/IB2020/050114 Ceased WO2020144591A2 (en) 2019-01-09 2020-01-08 Preparation of purified withanoside x from withania somnifera plant materials and its medicinal use for the treatment of health disorders

Country Status (1)

Country Link
WO (1) WO2020144591A2 (en)

Families Citing this family (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US20240058412A1 (en) * 2021-08-20 2024-02-22 Inventia Healthcare Limited Modified release formulation comprising withanolides
IT202300004452A1 (en) * 2023-03-09 2024-09-09 Neilos S R L NUTRACEUTIC OR PHARMACEUTICAL COMPOSITION FOR PHYSICAL AND MENTAL FATIGUE

Citations (5)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US20040166184A1 (en) * 2002-12-03 2004-08-26 Natreon Inc. Withania somnifera composition, method for obtaining same and pharmaceutical, nutritional and personal care formulations thereof
WO2008035354A1 (en) * 2006-09-21 2008-03-27 Unijules Life Sciences Ltd. Pellets of herbal extracts and process for preparing the same
WO2011077100A1 (en) * 2009-12-24 2011-06-30 Cipla Limited Antiretroviral composition
US20140348879A1 (en) * 2002-10-01 2014-11-27 Banner Pharmacaps, Inc. Enteric soft capsules
US20170326195A1 (en) * 2015-10-22 2017-11-16 Benny Antony A process to enhance the bioactivity of ashwagandha extracts

Patent Citations (5)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US20140348879A1 (en) * 2002-10-01 2014-11-27 Banner Pharmacaps, Inc. Enteric soft capsules
US20040166184A1 (en) * 2002-12-03 2004-08-26 Natreon Inc. Withania somnifera composition, method for obtaining same and pharmaceutical, nutritional and personal care formulations thereof
WO2008035354A1 (en) * 2006-09-21 2008-03-27 Unijules Life Sciences Ltd. Pellets of herbal extracts and process for preparing the same
WO2011077100A1 (en) * 2009-12-24 2011-06-30 Cipla Limited Antiretroviral composition
US20170326195A1 (en) * 2015-10-22 2017-11-16 Benny Antony A process to enhance the bioactivity of ashwagandha extracts

Also Published As

Publication number Publication date
WO2020144591A2 (en) 2020-07-16

Similar Documents

Publication Publication Date Title
AU2018260852B2 (en) A process to enhance the bioactivity of Ashwagandha extracts
WO2020144591A3 (en) Preparation of purified withanoside x from withania somnifera plant materials and its medicinal use
WO2008089268A3 (en) Methods and compositions for treating conditions associated with infection and/or inflammation
WO2009051837A3 (en) Vaccine nanotechnology
PH12012502085A1 (en) Method for preparing pharmaceutical compositions intended for oral administration comprising one or more active ingredients and the compositions comprising same
MX2010003923A (en) Pharmaceutical formulation of valsartan.
WO2013183062A3 (en) Palatable formulations of ibuprofen
MX2023003230A (en) Pro.
WO2019194773A3 (en) The combination comprising linagliptin and metformin
WO2010046933A3 (en) Pharmaceutical compositions of taste-masked linezolid
WO2012042197A3 (en) Low dose pharmaceutical composition comprising zanamivir
WO2016091805A3 (en) Naloxone monopreparation and multi-layer tablet
WO2019180688A3 (en) Compositions and methods for treating diarrheal diseases
WO2020190900A8 (en) Abiraterone-cyclic oligomer pharmaceutical formulations and methods of formation and administration thereof
WO2016175589A3 (en) Pharmaceutical composition for preventing or treating respiratory diseases, containing extract of mixed herbal medicines
PH12016502302A1 (en) Pharmaceutical composition for preventing and treating senile dementia and preparation method thereof
WO2019222801A9 (en) Promotion of epithelial repair via the administration of activators of pi3k/akt signalling
WO2016146562A1 (en) Gloriosa superba l. extracts, compositions and use thereof
WO2008014570A3 (en) Treatment and prevention of allergic airways diseases
WO2022123550A8 (en) Cannabidiol for augmenting vaccine mediated immunity and prophylaxis of covid-19
MX2021006464A (en) Polymorphic form of meisoindigo and modified formulation of meisoindigo.
Hassan et al. Phytochemical, Toxicological and In vitro Antifungal Studies of Mitracarpus hirtus L.
WO2007147404A3 (en) Pharmaceutical composition with an extracellular polyanion from arthrospira
WO2019055550A3 (en) Methods of preparing compositions containing thymoquinone
WO2019035143A3 (en) Medicated honey and method of preparation thereof

Legal Events

Date Code Title Description
121 Ep: the epo has been informed by wipo that ep was designated in this application

Ref document number: 20738840

Country of ref document: EP

Kind code of ref document: A2

NENP Non-entry into the national phase

Ref country code: DE

122 Ep: pct application non-entry in european phase

Ref document number: 20738840

Country of ref document: EP

Kind code of ref document: A2